Senior officials from the Trump administration say they have reached two important agreements with Eli Lilly and Novo Nordisk that will lower the prices of major obesity drugs.



These medicines have been in huge demand, but the high cost has kept many people from accessing them.

The new deals aim to ease that burden and expand availability for millions of Americans. If fully implemented, this could become one of the most meaningful healthcare shifts in years.

#USPolicy
#HealthUpdate
#DrugPricing
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)